PVI
FULC icon

Pura Vida Investments’s Fulcrum Therapeutics FULC Stock Holding History

Pura Vida Investments’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-126,068
Closed -$1.49M – 242
2021
Q1 		$1.49M Buy
126,068
+70,334
+126% +$870K 0.04% 177
2020
Q4 		$653K Buy
+55,734
New +$630K 0.02% 167

Other funds holding FULC

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Pura Vida Investments's FULC Position: Q2 2021 in Review

Pura Vida Investments sold out of Fulcrum Therapeutics (FULC) in Q2 2021, closing a stake of 126,068 shares — an estimated $1.49M sold.

Pura Vida Investments first reported a position in FULC in Q4 2020 and held it in 2 quarters. The position peaked at $1.49M in Q1 2021. 67 funds tracked by Wall St. Rank hold FULC as of Q2 2021.

  • Pura Vida Investments reported no remaining Fulcrum Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Pura Vida Investments sold 126,068 Fulcrum Therapeutics shares in Q2 2021, an estimated $1.49M.
  • Pura Vida Investments first reported a position in Fulcrum Therapeutics in Q4 2020 and held it in 2 quarters.
  • Pura Vida Investments's Fulcrum Therapeutics position peaked at $1.49M in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2021.

Based on Pura Vida Investments's 13F filing for Q2 2021, filed 16 Aug 2021.